Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29664987 | 0.87 | YTHDC1 (0.61) | YTHDC1NPC1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL29664965 | 0.87 | YTHDC1 (0.58) | YTHDC1NPC1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL18588084 | 0.87 | YTHDC1 (0.61) | YTHDC1NPC1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL18587539 | 0.87 | YTHDC1 (0.58) | YTHDC1NPC1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL18587532 | 0.86 | SMN1; SMN2 (0.62) | YTHDC1NPC1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL29659514 | 0.84 | YTHDC1 (0.66) | YTHDC1NPC1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL20547440 | 0.84 | YTHDC1 (0.66) | YTHDC1NPC1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL29664960 | 0.82 | YTHDC1 (0.59) | YTHDC1NPC1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL18587976 | 0.82 | YTHDC1 (0.59) | YTHDC1NPC1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL20547426 | 0.81 | NPC1 (0.68) | YTHDC1NPC1RAB9ASMN1; SMN2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3341371-B1 | ADENINE DERIVATIVES AND THEIR USE AS UV-PHOTOPROTECTIVE AGENTS | UNIV PALACKEHO (CZ) | 2022-06-29 | — | — | EP | claimed |
| US-20180298004-A1 | ADENINE DERIVATIVES AND THEIR USE AS UV-PHOTOPROTECTIVE AGENTS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2018-10-18 | — | — | US | claimed |
| EP-3341371-A1 | ADENINE DERIVATIVES AND THEIR USE AS UV-PHOTOPROTECTIVE AGENTS | Univerzita Palackého V Olomouci (CZ) | 2018-07-04 | — | — | EP | claimed |
| WO-2017036434-A1 | ADENINE DERIVATIVES AND THEIR USE AS UV-PHOTOPROTECTIVE AGENTS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2017-03-09 | — | — | WO | claimed |
| EP-3341371-B1 | ADENINE DERIVATIVES AND THEIR USE AS UV-PHOTOPROTECTIVE AGENTS | UNIV PALACKEHO (CZ) | 2022-06-29 | — | — | EP | disclosed |
| US-10774084-B2 | Adenine derivatives and their use as UV-photoprotective agents | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2020-09-15 | — | — | US | disclosed |
| US-20180298004-A1 | ADENINE DERIVATIVES AND THEIR USE AS UV-PHOTOPROTECTIVE AGENTS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2018-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180298004-A1 | ADENINE DERIVATIVES AND THEIR USE AS UV-PHOTOPROTECTIVE AGENTS | XPA, ERCC4, UNG | YTHDC1 459/4885NPC1 3189/4885RAB9A 252/4885 |
| US-10774084-B2 | Adenine derivatives and their use as UV-photoprotective agents | XPA, ERCC4, UNG | YTHDC1 398/4885NPC1 3283/4885RAB9A 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.